Rainier Acquisition Corporation RNAQ
- Market cap
- $115.5M
- P/E
- —
Follow RNAQ
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
Low Price | ||
| — | — | — | — | — | — | — | — | — | — | High Price | |||
| — | — | — | — | — | — | — | — | — | — | Employees | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Emp | |||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | — | — | EBT | |||
| — | — | — | — | — | — | — | — | — | — | EBT Margin | |||
| — | — | — | — | — | — | — | — | — | 0 |
Net Income
|
|||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Earnings/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Cash Flow/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Capex/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Free CF/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Book Value/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Shares | |||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | — | — | Op' Cash Flow | |||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | — | — | FCF | |||
| — | — | — | — | — | — | — | — | — | — | Working Cap' | |||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | — | — | Net Debt | |||
| — | — | — | — | — | — | — | — | — | — | Sh' Equity | |||
| — | — | — | — | — | — | — | — | — | — | ROA | |||
| — | — | — | — | — | — | — | — | — | — | ROIC | |||
| — | — | — | — | — | — | — | — | — | — | ROE | |||
Rainier Acquisition Corporation (RNAQ) Latest News
11 Sep
Rainier Acquisition Corporation announced that starting September 14, 2026, holders of its Units may separately trade the Class A ordinary shares (RNAQ) and warrants (RNAQW). Each Unit includes one Class A share and one-quarter of a redeemable warrant; no fractional warrants will be issued, and only whole warrants will trade. The Class A shares and warrants that are separated will begin trading on Nasdaq on September 15, 2026 under RNAQ and RNAQW, while unseparated Units will trade as RNAQU. Holders must contact Continental Stock Transfer & Trust to separate. Units began trading August 27, 2026. The IPO totaled 8,625,000 Units for $86.25 million in gross proceeds, with $86.25 million placed in the trust account; Chardan Capital Markets LLC acted as sole book-running manager. The SPAC aims to pursue a life sciences target. Separation of units into separately tradable shares and warrants could affect liquidity and valuation, a moderately influential but routine SPAC step.
28 Aug
Rainier Acquisition Corporation closed its initial public offering of 7,500,000 units at $10.00 per unit, raising $75 million gross. Each unit includes one Class A ordinary share and one-quarter of a redeemable warrant; each whole warrant may buy one Class A share at $11.50. The units began trading on Nasdaq Capital Market on Aug. 27, 2026 under the ticker RNAQU, with the Class A shares and warrants expected to list separately as RNAQ and RNAQW once trading separates. The SPAC intends to pursue a merger or other business combination, focusing on global life sciences—including therapeutics, diagnostics, genomics, precision medicine, life science tools, research services, and biomanufacturing—without geographic limits. Management is led by CEO Gbola Amusa and CFO Guy Barudin. Chardan acted as sole book-running manager. The underwriter has a 45-day option to purchase up to 1,125,000 additional units. Provides capital and listing credibility for a future business combination but ultimate value depends on target and execution.
26 Aug
Rainier Acquisition Corporation priced its IPO of 7.5 million units at $10.00 per unit, aiming gross proceeds of $75 million. Each unit includes one Class A ordinary share and 1/4 of a redeemable warrant exercisable at $11.50; no fractional warrants. Units will trade on Nasdaq as RNAQU starting Aug 27, 2026; when split, shares trade as RNAQ and warrants as RNAQW. Underwriters led by Chardan have a 45-day option to buy up to 1,125,000 additional units. The offering is expected to close on Aug 28, 2026. Rainier, a SPAC targeting life sciences businesses, is led by CEO Gbola Amusa and CFO Guy Barudin. A prospectus is available; forward-looking statements are cautioned. The $75 million IPO, Nasdaq listing, and over-allotment option materially enhance Rainier's capital runway for a future business combination and influence investor expectations.